# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 20, "Clin Drug Investig .", "", "<http://ctro/data#Publication_49090> <http://ctro/data#hasJournal> \"Clin Drug Investig .\"."
1, PublicationYear, 21, 25, "2013", "", "<http://ctro/data#Publication_49090> <http://ctro/data#hasPublicationYear> \"2013\"."
2, Saxagliptin, 99, 110, "Saxagliptin", "", 
27, Title, 99, 227, "Saxagliptin add - on therapy to insulin with or without metformin for type 2 diabetes mellitus : 52 - week safety and efficacy .", "", "<http://ctro/data#Publication_49090> <http://ctro/data#hasTitle> \"Saxagliptin add - on therapy to insulin with or without metformin for type 2 diabetes mellitus : 52 - week safety and efficacy .\"."
13, Insulin, 131, 138, "insulin", "", 
14, Metformin, 155, 164, "metformin", "", 
21, Type2Diabetes, 169, 193, "type 2 diabetes mellitus", "", "<http://ctro/data#ClinicalTrial_49097> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
26, Duration, 196, 205, "52 - week", "", "<http://ctro/data#ClinicalTrial_49097> <http://ctro/data#hasCTduration> \"52 - week\"."
28, Author, 228, 238, "Barnett AH", "", "<http://ctro/data#Publication_49090> <http://ctro/data#hasAuthor> \"Barnett AH\"."
29, Author, 247, 259, "Charbonnel B", "", "<http://ctro/data#Publication_49090> <http://ctro/data#hasAuthor> \"Charbonnel B\"."
30, Author, 262, 266, "Li J", "", "<http://ctro/data#Publication_49090> <http://ctro/data#hasAuthor> \"Li J\"."
31, Author, 269, 278, "Donovan M", "", "<http://ctro/data#Publication_49090> <http://ctro/data#hasAuthor> \"Donovan M\"."
32, Author, 281, 290, "Fleming D", "", "<http://ctro/data#Publication_49090> <http://ctro/data#hasAuthor> \"Fleming D\"."
33, Author, 293, 300, "Iqbal N", "", "<http://ctro/data#Publication_49090> <http://ctro/data#hasAuthor> \"Iqbal N\"."
34, UK, 450, 452, "UK", "", 
22, Type2Diabetes, 547, 571, "type 2 diabetes mellitus", "", 
23, Type2Diabetes, 574, 578, "T2DM", "", 
49, ObjectiveDescription, 595, 844, "The objective of this study was to evaluate the safety and efficacy of the dipeptidyl peptidase - 4 inhibitor saxagliptin versus placebo as add - on therapy in patients with T2DM inadequately controlled with insulin alone or insulin plus metformin .", "", "<http://ctro/data#ClinicalTrial_49097> <http://ctro/data#hasObjectiveDescription> \"The objective of this study was to evaluate the safety and efficacy of the dipeptidyl peptidase - 4 inhibitor saxagliptin versus placebo as add - on therapy in patients with T2DM inadequately controlled with insulin alone or insulin plus metformin .\"."
3, Saxagliptin, 705, 716, "saxagliptin", "", 
35, Placebo, 724, 731, "placebo", "", 
48, Precondition, 755, 842, "patients with T2DM inadequately controlled with insulin alone or insulin plus metformin", "", "<http://ctro/data#Population_49113> <http://ctro/data#hasPrecondition> \"patients with T2DM inadequately controlled with insulin alone or insulin plus metformin\"."
24, Type2Diabetes, 769, 773, "T2DM", "", 
46, Insulin, 803, 810, "insulin", "", 
47, Insulin, 820, 827, "insulin", "", 
15, Metformin, 833, 842, "metformin", "", 
50, Duration, 880, 889, "28 - week", "", 
51, Duration, 922, 931, "24 - week", "", 
52, Randomized, 936, 946, "randomized", "", "<http://ctro/data#ClinicalTrial_49097> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
53, DoubleBlind, 949, 963, "double - blind", "", "<http://ctro/data#ClinicalTrial_49097> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
54, Parallel, 966, 982, "parallel - group", "", "<http://ctro/data#ClinicalTrial_49097> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
4, Saxagliptin, 992, 1003, "saxagliptin", "", "<http://ctro/data#Medication_49151> <http://ctro/data#hasDrug> <http://ctro/data#Saxagliptin>."
55, DoseValue, 1004, 1005, "5", "", "<http://ctro/data#Medication_49151> <http://ctro/data#hasDoseValue> \"5\"."
56, mg, 1006, 1008, "mg", "", "<http://ctro/data#Medication_49151> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
57, Frequency, 1009, 1019, "once daily", "", 
36, Placebo, 1027, 1034, "placebo", "", "<http://ctro/data#Medication_49158> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
58, OpenLabel, 1058, 1070, "open - label", "", "<http://ctro/data#ClinicalTrial_49097> <http://ctro/data#hasCTDesign> <http://ctro/data#OpenLabel>."
59, Insulin, 1071, 1078, "insulin", "", 
60, Insulin, 1082, 1089, "insulin", "", 
37, Metformin, 1095, 1104, "metformin", "", 
61, Duration, 1122, 1130, "52 weeks", "", 
62, InsulinDose, 1196, 1210, "insulin dosage", "", 
63, InsulinDose, 1274, 1288, "insulin dosage", "", 
71, Precondition, 1463, 1650, "Patients with T2DM aged 18 - 78 years with glycated hemoglobin ( HbA1c ) 7 . 5 - 11 % on a stable insulin regimen ( 30 - 150 U / day with or without metformin ) for ≥ 8 weeks at screening", "", "<http://ctro/data#Population_49113> <http://ctro/data#hasPrecondition> \"Patients with T2DM aged 18 - 78 years with glycated hemoglobin ( HbA1c ) 7 . 5 - 11 % on a stable insulin regimen ( 30 - 150 U / day with or without metformin ) for ≥ 8 weeks at screening\"."
25, Type2Diabetes, 1477, 1481, "T2DM", "", 
64, MinAge, 1487, 1489, "18", "", "<http://ctro/data#Population_49113> <http://ctro/data#hasMinAge> \"18\"."
65, MaxAge, 1492, 1494, "78", "", "<http://ctro/data#Population_49113> <http://ctro/data#hasMaxAge> \"78\"."
196, Year, 1495, 1500, "years", "", 
66, HbA1c, 1506, 1525, "glycated hemoglobin", "", 
67, HbA1c, 1528, 1533, "HbA1c", "", 
68, Percentage, 1547, 1548, "%", "", 
70, InsulinDose, 1561, 1576, "insulin regimen", "", 
201, Insulin, 1561, 1568, "insulin", "", 
204, DoseValue, 1579, 1587, "30 - 150", "", 
69, BioAndMedicalUnit, 1588, 1595, "U / day", "", 
16, Metformin, 1612, 1621, "metformin", "", 
205, Duration, 1630, 1637, "8 weeks", "", 
72, Metformin, 1708, 1717, "metformin", "", 
73, Randomized, 1726, 1734, "randomly", "", 
74, AllocationRatio, 1744, 1749, "2 : 1", "", "<http://ctro/data#AllocationRatio_49101> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#AllocationRatio>. <http://ctro/data#ClinicalTrial_49097> <http://ctro/data#hasAllocationRatio> <http://ctro/data#AllocationRatio_49101>."
5, Saxagliptin, 1758, 1769, "saxagliptin", "", 
75, DoseValue, 1770, 1771, "5", "", 
76, mg, 1772, 1774, "mg", "", 
77, NumberPatientsArm, 1781, 1784, "304", "", "<http://ctro/data#Arm_49121> <http://ctro/data#hasNumberPatientsArm> \"304\"."
38, Placebo, 1790, 1797, "placebo", "", 
78, NumberPatientsArm, 1804, 1807, "151", "", "<http://ctro/data#Arm_49130> <http://ctro/data#hasNumberPatientsArm> \"151\"."
79, Frequency, 1810, 1820, "once daily", "", "<http://ctro/data#Intervention_49139> <http://ctro/data#hasFrequency> \"once daily\". <http://ctro/data#Intervention_49145> <http://ctro/data#hasFrequency> \"once daily\"."
80, Duration, 1862, 1870, "24 weeks", "", 
81, Duration, 1920, 1929, "28 - week", "", 
82, HbA1c, 2040, 2045, "HbA1c", "", 
83, TimePoint, 2051, 2059, "baseline", "", 
84, TimePoint, 2063, 2070, "week 52", "", 
85, TimePoint, 2121, 2128, "week 24", "", 
86, TimePoint, 2147, 2154, "week 52", "", 
225, Mean, 2166, 2170, "mean", "", "<http://ctro/data#Mean_49207> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_49205> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_49207>."
91, TimePoint, 2183, 2191, "baseline", "", 
92, HbA1c, 2192, 2197, "HbA1c", "", "<http://ctro/data#Endpoint_49205> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
87, TimePoint, 2201, 2208, "week 52", "", "<http://ctro/data#Outcome_49210> <http://ctro/data#hasTimePoint> \"week 52\"."
6, Saxagliptin, 2226, 2237, "saxagliptin", "", 
93, Reduction, 2242, 2248, "0 . 75", "", "<http://ctro/data#Outcome_49210> <http://ctro/data#hasChangeValue> \"0 . 75\"."
95, Percentage, 2249, 2250, "%", "", "<http://ctro/data#Endpoint_49205> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
39, Placebo, 2260, 2267, "placebo", "", 
94, Reduction, 2272, 2278, "0 . 38", "", "<http://ctro/data#Outcome_91542> <http://ctro/data#hasChangeValue> \"0 . 38\"."
96, Percentage, 2279, 2280, "%", "", 
97, DiffGroupAbsValue, 2329, 2337, "- 0 . 37", "", "<http://ctro/data#DiffBetweenGroups_49264> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 37\"."
98, Percentage, 2338, 2339, "%", "", 
99, ConfIntervalDiff, 2342, 2370, "95 % CI - 0 . 55 to - 0 . 19", "", "<http://ctro/data#DiffBetweenGroups_49264> <http://ctro/data#hasConfIntervalDiff> \"95 % CI - 0 . 55 to - 0 . 19\"."
244, SubGroupDescription, 2419, 2450, "patients treated with metformin", "", "<http://ctro/data#Outcome_49273> <http://ctro/data#hasSubGroupDescription> \"patients treated with metformin\". <http://ctro/data#Outcome_49300> <http://ctro/data#hasSubGroupDescription> \"patients treated with metformin\"."
17, Metformin, 2441, 2450, "metformin", "", 
100, DiffGroupAbsValue, 2453, 2461, "- 0 . 37", "", "<http://ctro/data#DiffBetweenGroups_49381> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 37\"."
105, Percentage, 2462, 2463, "%", "", 
106, ConfIntervalDiff, 2466, 2494, "95 % CI - 0 . 59 to - 0 . 15", "", "<http://ctro/data#DiffBetweenGroups_49381> <http://ctro/data#hasConfIntervalDiff> \"95 % CI - 0 . 59 to - 0 . 15\"."
103, SubGroupDescription, 2503, 2520, "without metformin", "", "<http://ctro/data#Outcome_49327> <http://ctro/data#hasSubGroupDescription> \"without metformin\". <http://ctro/data#Outcome_49354> <http://ctro/data#hasSubGroupDescription> \"without metformin\"."
101, DiffGroupAbsValue, 2523, 2531, "- 0 . 37", "", "<http://ctro/data#DiffBetweenGroups_49390> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 37\"."
104, Percentage, 2532, 2533, "%", "", 
107, ConfIntervalDiff, 2536, 2564, "95 % CI - 0 . 69 to - 0 . 04", "", "<http://ctro/data#DiffBetweenGroups_49390> <http://ctro/data#hasConfIntervalDiff> \"95 % CI - 0 . 69 to - 0 . 04\"."
88, TimePoint, 2574, 2581, "week 52", "", "<http://ctro/data#Outcome_49404> <http://ctro/data#hasTimePoint> \"week 52\". <http://ctro/data#Outcome_49431> <http://ctro/data#hasTimePoint> \"week 52\"."
7, Saxagliptin, 2627, 2638, "saxagliptin", "", 
108, HbA1c_target, 2648, 2659, "HbA1c < 7 %", "", "<http://ctro/data#Endpoint_49399> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
252, Percentage, 2658, 2659, "%", "", 
40, Placebo, 2681, 2688, "placebo", "", 
109, PercentageAffected, 2691, 2697, "21 . 3", "", "<http://ctro/data#Outcome_49404> <http://ctro/data#hasPercentageAffected> \"21 . 3\"."
110, PercentageAffected, 2703, 2708, "8 . 7", "", "<http://ctro/data#Outcome_49431> <http://ctro/data#hasPercentageAffected> \"8 . 7\"."
111, DiffGroupRelValue, 2740, 2746, "12 . 6", "", "<http://ctro/data#DiffBetweenGroups_49458> <http://ctro/data#hasDiffGroupRelValue> \"12 . 6\"."
112, ConfIntervalDiff, 2751, 2773, "95 % CI 6 . 1 - 19 . 1", "", "<http://ctro/data#DiffBetweenGroups_49458> <http://ctro/data#hasConfIntervalDiff> \"95 % CI 6 . 1 - 19 . 1\"."
113, TimePoint, 2798, 2806, "baseline", "", 
261, Mean, 2810, 2814, "mean", "", "<http://ctro/data#Mean_49469> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_49467> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_49469>."
114, InsulinDose, 2827, 2839, "insulin dose", "", "<http://ctro/data#InsulinDose_49468> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#InsulinDose>. <http://ctro/data#Endpoint_49467> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#InsulinDose_49468>."
89, TimePoint, 2843, 2850, "week 52", "", "<http://ctro/data#Outcome_49472> <http://ctro/data#hasTimePoint> \"week 52\". <http://ctro/data#Outcome_49499> <http://ctro/data#hasTimePoint> \"week 52\"."
8, Saxagliptin, 2880, 2891, "saxagliptin", "", 
115, ResultMeasuredValue, 2894, 2900, "5 . 67", "", "<http://ctro/data#Outcome_49472> <http://ctro/data#hasResultMeasuredValue> \"5 . 67\"."
116, ResultMeasuredValue, 2904, 2910, "6 . 67", "", "<http://ctro/data#Outcome_49499> <http://ctro/data#hasResultMeasuredValue> \"6 . 67\"."
268, Int_Unit, 2911, 2912, "U", "", "<http://ctro/data#Endpoint_49467> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Int_Unit>."
41, Placebo, 2918, 2925, "placebo", "", 
118, DiffGroupAbsValue, 2941, 2949, "- 1 . 01", "", "<http://ctro/data#DiffBetweenGroups_49526> <http://ctro/data#hasDiffGroupAbsValue> \"- 1 . 01\"."
269, Int_Unit, 2950, 2951, "U", "", 
120, ConfIntervalDiff, 2954, 2980, "95 % CI - 3 . 24 to 1 . 22", "", "<http://ctro/data#DiffBetweenGroups_49526> <http://ctro/data#hasConfIntervalDiff> \"95 % CI - 3 . 24 to 1 . 22\"."
90, TimePoint, 2998, 3007, "52 - week", "", "<http://ctro/data#Outcome_49540> <http://ctro/data#hasTimePoint> \"52 - week\". <http://ctro/data#Outcome_49567> <http://ctro/data#hasTimePoint> \"52 - week\"."
121, EndPointDescription, 3060, 3077, "≥ 1 adverse event", "", "<http://ctro/data#EndPointDescription_49536> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_49535> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_49536>."
122, EndPointDescription, 3080, 3082, "AE", "", "<http://ctro/data#EndPointDescription_49536> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_49535> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_49536>."
123, PercentageAffected, 3089, 3095, "66 . 4", "", "<http://ctro/data#Outcome_49540> <http://ctro/data#hasPercentageAffected> \"66 . 4\"."
9, Saxagliptin, 3103, 3114, "saxagliptin", "", 
124, PercentageAffected, 3119, 3125, "71 . 5", "", "<http://ctro/data#Outcome_49567> <http://ctro/data#hasPercentageAffected> \"71 . 5\"."
42, Placebo, 3133, 3140, "placebo", "", 
20, Saxagliptin, 3227, 3238, "saxagliptin", "", 
43, Placebo, 3242, 3249, "placebo", "", 
67694, EndPointDescription, 3257, 3280, "urinary tract infection", "", 
67696, EndPointDescription, 3283, 3298, "nasopharyngitis", "", 
67697, EndPointDescription, 3301, 3334, "upper respiratory tract infection", "", 
67698, Headache, 3337, 3345, "headache", "", 
67699, EndPointDescription, 3348, 3357, "influenza", "", 
67700, EndPointDescription, 3364, 3381, "pain in extremity", "", 
67686, ObservedResult, 3384, 3445, "the incidence of each AE was similar between treatment groups", "", 
10, Saxagliptin, 3455, 3466, "saxagliptin", "", 
44, Placebo, 3471, 3478, "placebo", "", 
129, Hypoglycemia, 3514, 3526, "hypoglycemia", "", "<http://ctro/data#Endpoint_49594> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
130, PercentageAffected, 3531, 3537, "22 . 7", "", "<http://ctro/data#Outcome_49599> <http://ctro/data#hasPercentageAffected> \"22 . 7\"."
131, PercentageAffected, 3542, 3548, "26 . 5", "", "<http://ctro/data#Outcome_49626> <http://ctro/data#hasPercentageAffected> \"26 . 5\"."
132, Hypoglycemia, 3595, 3607, "hypoglycemia", "", "<http://ctro/data#Endpoint_49653> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
135, Mg_per_deciliter, 3635, 3642, "mg / dL", "", 
136, Millimoles_per_litre, 3653, 3661, "mmol / L", "", 
133, PercentageAffected, 3699, 3704, "7 . 6", "", "<http://ctro/data#Outcome_49658> <http://ctro/data#hasPercentageAffected> \"7 . 6\"."
134, PercentageAffected, 3709, 3714, "6 . 6", "", "<http://ctro/data#Outcome_49685> <http://ctro/data#hasPercentageAffected> \"6 . 6\"."
294, Mean, 3743, 3747, "mean", "", "<http://ctro/data#Mean_49714> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_49712> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_49714>."
138, TimePoint, 3760, 3768, "baseline", "", 
139, BodyWeight, 3769, 3780, "body weight", "", "<http://ctro/data#Endpoint_49712> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
140, Increment, 3787, 3792, "0 . 8", "", "<http://ctro/data#Outcome_49717> <http://ctro/data#hasChangeValue> \"0 . 8\"."
142, Kg, 3793, 3795, "kg", "", "<http://ctro/data#Endpoint_49712> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Kg>."
11, Saxagliptin, 3801, 3812, "saxagliptin", "", 
141, Increment, 3819, 3824, "0 . 5", "", "<http://ctro/data#Outcome_49744> <http://ctro/data#hasChangeValue> \"0 . 5\"."
143, Kg, 3825, 3827, "kg", "", 
45, Placebo, 3833, 3840, "placebo", "", 
12, Saxagliptin, 3856, 3867, "Saxagliptin", "", 
149, ConclusionComment, 3856, 4051, "Saxagliptin 5 mg once daily as add - on to insulin , with or without concomitant metformin , produced a durable improvement in glycemic control and was well tolerated over 52 weeks of treatment .", "", "<http://ctro/data#ClinicalTrial_49097> <http://ctro/data#hasConclusionComment> \"Saxagliptin 5 mg once daily as add - on to insulin , with or without concomitant metformin , produced a durable improvement in glycemic control and was well tolerated over 52 weeks of treatment .\"."
144, DoseValue, 3868, 3869, "5", "", 
145, mg, 3870, 3872, "mg", "", 
146, Frequency, 3873, 3883, "once daily", "", 
147, Insulin, 3899, 3906, "insulin", "", 
19, Metformin, 3937, 3946, "metformin", "", 
148, Duration, 4028, 4036, "52 weeks", "", 
150, PMID, 4101, 4109, "23949898", "", "<http://ctro/data#Publication_49090> <http://ctro/data#hasPMID> \"23949898\"."
